{"rewrite":{"id":"r_eaeeaeacc2fdb6cfb59909f5","clusterId":"c_d162e6e80cb89b164481f1f2","slug":"radionano-therapeutics-closes-first-series-b-tranche","model":"deepseek-v4-1-flash","headline":"RadioNano Therapeutics Closes First Series B Tranche","summary":"RadioNano Therapeutics, a Kyoto-based company developing boron agents for boron neutron capture therapy, completed the first close of a Series B round through a third-party allotment of new shares. Mitsui Mining \u0026 Smelting and Kyoto University Innovation Capital subscribed. The amount raised is undisclosed. Funds go to a Phase I/IIa trial of RN-501, the lead pipeline, and the company will keep fundraising toward a second close.","whyItMatters":"The first close moves RN-501 from non-clinical work toward a Phase I/IIa trial, and the subscription by a smelting company alongside a university-affiliated fund pairs materials manufacturing capacity with early-stage life science capital.","webCardHtml":"\u003cp\u003eMitsui Mining \u0026amp; Smelting and Kyoto University Innovation Capital took new shares in the placement. RadioNano did not disclose the amount. The company says the money covers a Phase I/IIa trial of RN-501, a GMP manufacturing and supply system for the investigational drug, and additional development staff.\u003c/p\u003e\u003cp\u003eBNCT kills cancer cells through the reaction between thermal neutrons and boron-10, and Japan approved it for insurance-covered care in 2020. RadioNano is developing RN-501 as a boron-rich inorganic nanoparticle formulation based on Kyoto University research, and has held regulatory science consultations with the PMDA.\u003c/p\u003e","blueskyPost":"Mitsui Mining \u0026 Smelting is a metals company, not a life sciences fund, which makes its subscription in RadioNano Therapeutics' Series B a bet on boron supply as much as on RN-501's trial.","twitterPost":"Mitsui Mining \u0026 Smelting, a metals firm, is backing RadioNano Therapeutics' Series B, tying the boron agent supply chain to the RN-501 trial.","threadsPost":"Mitsui Mining \u0026 Smelting subscribing to RadioNano Therapeutics' Series B puts a metals producer inside a drug developer's cap table. Boron is the active material in RN-501, so the investor and the supply chain sit in the same room before the Phase I/IIa trial starts.","newsletterBlurb":"RadioNano Therapeutics completed the first close of its Series B round through a third-party share allotment, with Mitsui Mining \u0026 Smelting and Kyoto University Innovation Capital subscribing. The raise is undisclosed and earmarked for a Phase I/IIa trial of RN-501, the company's lead boron agent for boron neutron capture therapy. A second close is still to come.","attributionJson":"[{\"source\":\"ASCII.jp\",\"url\":\"https://ascii.jp/elem/000/004/441/4441625/?rss\",\"title\":\"RadioNano Therapeutics Completes First Close of Series B Round\"}]","lintFlagsJson":null,"lintHits":0,"costUsd":0,"inputTokens":4561,"outputTokens":576,"status":"published","repairAttempts":0,"nextRepairAt":null,"factsAttemptedAt":1791537725,"createdAt":"2026-10-09T09:16:59.000Z","publishedAt":"2026-10-09T09:21:05.000Z","updatedAt":"2026-10-09T09:21:05.000Z"},"cluster":{"id":"c_d162e6e80cb89b164481f1f2","canonicalTitle":"RadioNano Therapeutics、シリーズBラウンドのファーストクローズを完了","representativeArticleId":"a_aa7baa4814ebf3206423fb40","sourceCount":1,"writtenSourceCount":1,"writeAttempts":0,"isSolo":true,"entitiesJson":"{\"anime_titles\":[],\"manga_titles\":[],\"work_titles\":[],\"studios\":[],\"people\":[],\"type\":\"business\",\"domain\":\"other\",\"is_roundup\":false}","contentType":"news","status":"published","firstSeenAt":"2026-10-09T06:30:00.000Z","lastSeenAt":"2026-10-09T06:30:00.000Z","updatedAt":"2026-10-09T09:21:06.000Z"},"attribution":[{"source":"ASCII.jp","url":"https://ascii.jp/elem/000/004/441/4441625/?rss","title":"RadioNano Therapeutics、シリーズBラウンドのファーストクローズを完了"}],"entities":{"anime_titles":[],"manga_titles":[],"work_titles":[],"studios":[],"people":[],"type":"business","domain":"other","is_roundup":false},"keyFacts":null}